MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

agree a paediatric investigation plan and grant a deferral

MHRA-100244-PIP01-21

Scope of the Application

Active Substance(s)

surufatinib

Condition(s)

Treatment of malignant neoplasms, Malignant neoplasms of haematopoietic and lymphoid tissue

Pharmaceutical Form(s)

Capsule, hard, Powder for oral suspension

Route(s) of Administration

Oral use

Name / Corporate name of the PIP applicant

HUTCHMED Europe B.V.

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, HUTCHMED Europe B.V. submitted to the licensing authority on 15/10/2021 17:17 BST an application for a Paediatric Investigation Plan

The procedure started on 07/03/2022 13:01 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Final Decision Letter

MHRA-100244-PIP01-21

Of 20/04/2022 15:42 BST

On the adopted decision for surufatinib (MHRA-100244-PIP01-21) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for surufatinib, Capsule, hard, Powder for oral suspension , Oral use .

This decision is addressed to HUTCHMED Europe B.V., Nijborg 17, Renswoude, Netherlands, 3927 DA

ANNEX I

1. Waiver

1.1 Condition:

Not applicable to both conditions.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Condition 1 Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms) Condition 2 Treatment of malignant neoplasms of haematopoietic and lymphoid tissue

2.2 Indication(s) targeted by the PIP:

Condition 1: Treatment of paediatric patients from birth to less than 18 years of age with a paediatric solid tumour known or expected to have dysfunctional signalling pathways targeted by

surufatinib. Condition 2: Treatment of paediatric patients from birth to less than 18 years of age with lymphoma

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

For both conditions: The paediatric population from birth to less than 18 years of age

2.4 Pharmaceutical Form(s):

For both conditions: Capsule, hard; Powder for oral suspension Same studies for both conditions.

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	2	Study 1 Development of a 25 mg capsule of size 3, to improve dosing accuracy in paediatric clinical studies. Additionally feasibility study of smaller capsule size for 25 mg capsule, to improve the dosing compliance in the paediatric population. Study 2 Development of an oral suspension prepared from contents of 25 mg and 50 mg capsules.
Non-Clinical Studies	2	Study 3 Dose range-finding juvenile toxicity study to establish the doses to be used in the definitive juvenile study. Study 4 Definitive juvenile toxicity study to assess the potential effects of surufatinib on growth and maturation of developing organ systems.
Clinical Studies	2	Study 5 Open label multiple dose, uncontrolled trial to evaluate the pharmacokinetics, safety, activity, and acceptability/ palatability of surufatinib in combination with gemcitabine in children from birth to less than 18 years of age with recurrent or refractory solid tumours known or expected to have dysfunctional signalling pathways targeted by surufatinib, including lymphoma. Study 6 Open label, randomised, active control study to evaluate the efficacy and safety of surufatinib in combination with gemcitabine compared to standard

		of care in children from birth to less than 18 years of age with a paediatric solid tumour selected on the basis of the results from Study 5.
Extrapolation, Modeling & Simulation Studies	1	Study 7 Population based modelling and simulation study to predict and characterise surufatinib pharmacokinetics (PK) in the paediatric population from birth to less than 18 years of age.
Other Studies	0	Not applicable
Other Measures	0	Not applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	31/01/2028
Deferral of one or more studies contained in the paediatric investigation plan:	Yes